Mannkind (MNKD) Construction in Progress (2021 - 2022)

Mannkind (MNKD) posted quarterly Construction in Progress of $7.7 million for Q1 2022, up 63.83% quarter-over-quarter from $4.7 million in Q4 2021.

Mannkind (MNKD) Construction in Progress (2021 - 2022) Analysis & Trends

Mannkind (MNKD) has reported Construction in Progress for 2 consecutive years, with $7.7 million the latest figure, recorded in Q1 2022.

In Q1 2022, Construction in Progress changed N/A year-over-year to $7.7 million; the TTM figure through Mar 2022 stood at $7.7 million (changed N/A YoY), while the FY2021 annual figure was $4.7 million, changed N/A from the prior year.
Construction in Progress climbed to $7.7 million in Q1 2022 per MNKD's latest filing, from $4.7 million in the prior quarter.
Across five years, Construction in Progress topped out at $7.7 million in Q1 2022 and bottomed at $1.6 million in Q3 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Construction in Progress (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	-
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	152.67 Mn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-
10	Mannkind	1.19 Bn	1.08 Bn	94.97 Mn	-

Download Data